| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1084826380 |
| P356 | DOI | 10.1186/S13073-017-0424-2 |
| P932 | PMC publication ID | 5395719 |
| P698 | PubMed publication ID | 28420421 |
| P50 | author | Yuting He | Q64025704 |
| Juliann Chmielecki | Q66809335 | ||
| Levi A Garraway | Q89916155 | ||
| Uri Tabori | Q43826656 | ||
| P2093 | author name string | Siraj M Ali | |
| Vincent A Miller | |||
| Jeffrey S Ross | |||
| Adam Shlien | |||
| Caitlin F Connelly | |||
| Daniel S Lieber | |||
| Laurie Gay | |||
| Garrett M Frampton | |||
| Zachary R Chalmers | |||
| David Fabrizio | |||
| Brittany Campbell | |||
| Alexa Schrock | |||
| James Sun | |||
| Franklin Huang | |||
| Mark Kennedy | |||
| Jared White | |||
| Phillip J Stephens | |||
| Steven Roels | |||
| Geoffrey A Otto | |||
| Riley Ennis | |||
| P2860 | cites work | First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity | Q21245463 |
| The DNA-damage response in human biology and disease | Q24606586 | ||
| The Cancer Genome Atlas Pan-Cancer analysis project | Q24606808 | ||
| Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 | ||
| Melanoma genome sequencing reveals frequent PREX2 mutations | Q24610463 | ||
| Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas | Q24617520 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website | Q24645514 | ||
| Yeast DNA polymerase epsilon participates in leading-strand DNA replication | Q24652913 | ||
| Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 | ||
| Statistical significance for genomewide studies | Q24681264 | ||
| Analysis of protein-coding genetic variation in 60,706 humans | Q26831376 | ||
| The structural basis of modified nucleosome recognition by 53BP1 | Q27722410 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Mutational signatures associated with tobacco smoking in human cancer | Q28005544 | ||
| Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers | Q28256331 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers | Q28286394 | ||
| DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer | Q28287769 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database | Q29616468 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Improved variant discovery through local re-alignment of short-read next-generation sequencing data using SRMA | Q33713232 | ||
| p53 and human cancer: the first ten thousand mutations. | Q33767112 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| Lynch syndrome: genetics, natural history, genetic counseling, and prevention. | Q48371688 | ||
| Drastic genetic instability of tumors and normal tissues in Turcot syndrome | Q48570250 | ||
| Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. | Q53420486 | ||
| Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes | Q71733947 | ||
| Cancer, cadmium and genome integrity | Q73588691 | ||
| Retroviral recombination: what drives the switch? | Q73626301 | ||
| Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. | Q34399850 | ||
| A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors | Q34483473 | ||
| Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance | Q34486552 | ||
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Q34522172 | ||
| Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity | Q34554995 | ||
| Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability | Q34617569 | ||
| A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma | Q34982679 | ||
| Role of DNA mismatch repair defects in the pathogenesis of human cancer | Q35085461 | ||
| Recurrent somatic mutations in regulatory regions of human cancer genomes | Q35797838 | ||
| Highly penetrant hereditary cancer syndromes. | Q35868041 | ||
| CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma | Q35871798 | ||
| PD-1/PD-L1 inhibitors. | Q35893753 | ||
| Fast, scalable prediction of deleterious noncoding variants from functional and population genomic data | Q36306108 | ||
| Predicting effects of noncoding variants with deep learning-based sequence model | Q36621822 | ||
| DNA polymerases and cancer. | Q37084895 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| Therapeutic targeting of the DNA mismatch repair pathway | Q37786127 | ||
| CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? | Q38252348 | ||
| Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. | Q38259896 | ||
| Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade | Q38377528 | ||
| Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting | Q38381729 | ||
| PD-L1 blockade for cancer treatment: MEDI4736. | Q38475127 | ||
| Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. | Q38475150 | ||
| Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. | Q38620878 | ||
| 53BP1 fosters fidelity of homology-directed DNA repair | Q38761656 | ||
| Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. | Q38765494 | ||
| An integrative approach to predicting the functional effects of non-coding and coding sequence variation | Q40518007 | ||
| Mismatch repair, genetic stability, and cancer | Q40556409 | ||
| Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. | Q40720876 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 | Q41589138 | ||
| A common cancer-associated DNA polymerase ε mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading | Q41990410 | ||
| MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast | Q42427955 | ||
| Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma | Q42874163 | ||
| Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations | Q43130702 | ||
| Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors | Q44383505 | ||
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing | Q47163678 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 34 | |
| P577 | publication date | 2017-04-19 | |
| P1433 | published in | Genome Medicine | Q15816848 |
| P1476 | title | Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden | |
| P478 | volume | 9 |
| Q90228199 | "Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway |
| Q64882389 | A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. |
| Q90748872 | A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning |
| Q90220309 | A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma |
| Q64087984 | A decade of Genome Medicine: toward precision medicine |
| Q94600673 | A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma |
| Q90220299 | A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab |
| Q98945176 | A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases |
| Q55092262 | A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. |
| Q59798122 | A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay |
| Q89723592 | A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo |
| Q64103643 | A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors |
| Q46603813 | ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy |
| Q61813753 | APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy |
| Q89947196 | ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy |
| Q64121636 | Aberrant , , and Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer |
| Q88310940 | Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing |
| Q47162757 | Actionable mutations in canine hemangiosarcoma. |
| Q58787920 | Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy |
| Q90398709 | Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours |
| Q90010437 | Alterations of T-cell-mediated immunity in acute myeloid leukemia |
| Q92602032 | An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies |
| Q92713865 | An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients |
| Q91651772 | Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy |
| Q64948264 | Analysis of public RNA-sequencing data reveals biological consequences of genetic heterogeneity in cell line populations. |
| Q97539880 | Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing |
| Q57171692 | Ancillary studies in cytology: Secondary or necessary? |
| Q94503507 | Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma |
| Q83226948 | Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction |
| Q93052202 | Apparent Lack of BRAF V600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis |
| Q92796464 | Application of PD-1 Blockade in Cancer Immunotherapy |
| Q59798112 | Approach to evaluating tumor mutational burden in routine clinical practice |
| Q64247150 | Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel |
| Q92811896 | Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision? |
| Q64065785 | Assessment of tumor mutation burden calculation from gene panel sequencing data |
| Q92770087 | Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden |
| Q92666578 | Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay |
| Q52721217 | Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. |
| Q92967590 | Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database |
| Q47264823 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial |
| Q58806091 | Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition |
| Q93094401 | Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer |
| Q92134617 | Biomarker for personalized immunotherapy |
| Q48316037 | Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology. |
| Q99638760 | Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer |
| Q48168816 | Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. |
| Q49842940 | Blood- and tissue-based tumor genomics: a battle royale or match made in heaven? |
| Q92356109 | Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer |
| Q90788586 | Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab |
| Q89835069 | Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy |
| Q52385841 | Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic. |
| Q64077856 | Burden of unique and low prevalence somatic mutations correlates with cancer survival |
| Q93024707 | CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma |
| Q48185876 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth |
| Q96576321 | CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma |
| Q99202583 | CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features |
| Q95933724 | CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma |
| Q60489257 | Cancer immunoediting and resistance to T cell-based immunotherapy |
| Q93049163 | Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution |
| Q89081284 | Cancer-mutation network and the number and specificity of driver mutations |
| Q92821156 | Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia |
| Q93083714 | Case report: mutation analysis of primary pulmonary lymphoepithelioma-like carcinoma via whole-exome sequencing |
| Q92737181 | Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial |
| Q93083400 | Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer |
| Q99565899 | Challenges of PD-L1 testing in non-small cell lung cancer and beyond |
| Q52666942 | Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. |
| Q101564136 | Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing |
| Q59791226 | Chondrosarcoma: biology, genetics, and epigenetics |
| Q92177210 | Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis |
| Q92339671 | Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer |
| Q88355005 | Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers |
| Q90730544 | Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma |
| Q57143867 | Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy |
| Q98949426 | Clinical trials in urological oncology: COVID-19 and the potential need for a new perspective |
| Q100455164 | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies |
| Q64286918 | Clinical utility of custom-designed NGS panel testing in pediatric tumors |
| Q64983989 | Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. |
| Q59798138 | Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy |
| Q92578527 | Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy |
| Q55306266 | Colorectal cancer genomics and designing rational trials. |
| Q88010589 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma |
| Q96167192 | Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer |
| Q90693888 | Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report |
| Q55287125 | Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. |
| Q64074796 | Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer |
| Q90690161 | Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort |
| Q46592106 | Comprehensive Analysis of Hypermutation in Human Cancer |
| Q93051878 | Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer |
| Q61814605 | Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials |
| Q64075323 | Comprehensive analysis of age-related somatic mutation profiles in Chinese young lung adenocarcinoma patients |
| Q91599315 | Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer |
| Q102220308 | Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib |
| Q93137581 | Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy |
| Q91193210 | Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility |
| Q92593276 | Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice |
| Q90981691 | Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches |
| Q91832719 | Constrained De Novo Sequencing of neo-Epitope Peptides using Tandem Mass Spectrometry |
| Q60910622 | Correlate tumor mutation burden with immune signatures in human cancers |
| Q99237757 | Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer |
| Q90413950 | Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer |
| Q49626462 | Current and emerging trends in prostate cancer immunotherapy |
| Q55715408 | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. |
| Q61810141 | Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors |
| Q91934045 | DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor |
| Q92603273 | DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis |
| Q93047925 | DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade |
| Q97530925 | DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden |
| Q89186774 | DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer |
| Q57057014 | DNA repair defects and implications for immunotherapy |
| Q92782244 | DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer |
| Q92632787 | Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature |
| Q92458124 | Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy' |
| Q93159937 | Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma |
| Q58609277 | Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic |
| Q89511089 | Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark |
| Q89454912 | Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC |
| Q89505169 | EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients |
| Q98222326 | EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma |
| Q98892917 | Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis |
| Q94671901 | Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors |
| Q91756103 | Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer |
| Q47133172 | Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas |
| Q91933365 | Emerging trends in immunotherapy for pediatric sarcomas |
| Q48101797 | Environmental effects of ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2017. |
| Q90690081 | Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project |
| Q92608513 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors |
| Q90172065 | Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis |
| Q93087677 | FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape |
| Q92055538 | FIREVAT: finding reliable variants without artifacts in human cancer samples using etiologically relevant mutational signatures |
| Q64083862 | Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study |
| Q91747493 | First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers |
| Q54269200 | Frameshift events predict anti-PD-1/L1 response in head and neck cancer. |
| Q100426629 | From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm |
| Q97644572 | Gastric Cancer Tumor Microenvironment Characterization Reveals Stromal-Related Gene Signatures Associated With Macrophage Infiltration |
| Q49787556 | Gene aberration profile of tumors of adolescent and young adult females. |
| Q104073425 | Genetic and epigenetic determinants of diffuse large B-cell lymphoma |
| Q93216207 | Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer |
| Q64228432 | Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance |
| Q64099283 | Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population |
| Q52587406 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. |
| Q58106210 | Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy |
| Q52859649 | Genomic Profiling of Small-Bowel Adenocarcinoma. |
| Q92933838 | Genomic analysis of pancreatic juice DNA assesses malignant risk of intraductal papillary mucinous neoplasm of pancreas |
| Q90815056 | Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes |
| Q64247488 | Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition |
| Q102320151 | Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma |
| Q90197854 | Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss |
| Q104486516 | Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q91940770 | Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer |
| Q92767610 | Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer |
| Q90573204 | High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma |
| Q92889744 | Highlights of thoracic oncology from the 2018 ERS International Congress |
| Q47222791 | Hitting the Target: How T Cells Detect and Eliminate Tumors |
| Q101155775 | Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers |
| Q52655439 | Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. |
| Q89647127 | Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? |
| Q61805777 | IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine |
| Q93054534 | Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment |
| Q94475919 | Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma |
| Q94571796 | Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma |
| Q92640003 | Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma |
| Q57022602 | Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes |
| Q89940636 | Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies |
| Q92591182 | Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer |
| Q92512470 | Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types |
| Q64226690 | Identification of the Germline Mutation Profile in Esophageal Squamous Cell Carcinoma by Whole Exome Sequencing |
| Q55381932 | Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. |
| Q64885788 | Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. |
| Q98945440 | Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive EGFR/ALK Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report |
| Q90383103 | Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System |
| Q98771634 | Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer |
| Q53695267 | Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. |
| Q93270162 | Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma |
| Q92236896 | Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges |
| Q55260269 | Immune checkpoint inhibitors in small cell lung cancer. |
| Q55418935 | Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. |
| Q88497999 | Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough |
| Q57168423 | Immunological-based approaches for cancer therapy |
| Q89702021 | Immunotherapeutic approaches for small-cell lung cancer |
| Q92315030 | Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold? |
| Q91239730 | Immunotherapy for advanced penile cancer - rationale and potential |
| Q47555498 | Immunotherapy for brain tumors: understanding early successes and limitations |
| Q92895403 | Immunotherapy for hematological malignancies |
| Q90428542 | Immunotherapy for mucosal melanoma |
| Q47800676 | Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition |
| Q89910785 | Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? |
| Q90292724 | Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors |
| Q47235804 | Implementation of "Clinical Sequencing" in Cancer Genome Medicine in Japan |
| Q64229216 | Implementing TMB measurement in clinical practice: considerations on assay requirements |
| Q59798115 | Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians |
| Q93017232 | In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients |
| Q92947118 | Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis |
| Q92087496 | Integrated Epigenome, Exome, and Transcriptome Analyses Reveal Molecular Subtypes and Homeotic Transformation in Uterine Fibroids |
| Q60051000 | Intratumoral CD56 natural killer cells are associated with improved survival in bladder cancer |
| Q92857735 | Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer? |
| Q92570452 | KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy |
| Q64120316 | KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition |
| Q90642659 | LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype |
| Q88013125 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers |
| Q47153925 | Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology |
| Q93048382 | Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives |
| Q64886119 | Liquid biopsies for hepatocellular carcinoma. |
| Q93035206 | Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer |
| Q90661815 | Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome |
| Q60909766 | Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays |
| Q59798127 | Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy |
| Q93164050 | Mechanisms and therapeutic implications of hypermutation in gliomas |
| Q49994174 | Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage |
| Q96126883 | Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations |
| Q54976847 | Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. |
| Q54115719 | Melanoma: What do all the mutations mean? |
| Q89983780 | Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles |
| Q92901917 | Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men |
| Q59798095 | Methods of measurement for tumor mutational burden in tumor tissue |
| Q55264193 | Microsatellite instability in prostate cancer by PCR or next-generation sequencing. |
| Q50049563 | Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. |
| Q42353279 | Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances |
| Q92757665 | Microsatellite instability: a review of what the oncologist should know |
| Q92576171 | Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy |
| Q64990522 | Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. |
| Q64228131 | Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma |
| Q97419819 | Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma |
| Q50027697 | Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing |
| Q92799371 | Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma |
| Q64086109 | Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers |
| Q93078485 | Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas |
| Q63366116 | Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’ |
| Q61810151 | Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update |
| Q58107960 | Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer |
| Q55209571 | Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. |
| Q90215713 | Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study |
| Q90283161 | Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives |
| Q94593616 | Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer |
| Q64079285 | Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma |
| Q55156355 | Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. |
| Q90186863 | Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype |
| Q63499786 | Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series |
| Q89777376 | Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets |
| Q55261882 | Mutation load estimation model as a predictor of the response to cancer immunotherapy. |
| Q64386735 | Mutational burden and signatures in 4,000 Japanese cancers provide insights into tumorigenesis and response to therapy |
| Q92188170 | Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma |
| Q64939633 | Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. |
| Q92684416 | Mutational landscape of head and neck squamous cell carcinomas in a South Asian population |
| Q83230246 | Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF oncoprotein kinase |
| Q57232070 | Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma |
| Q92691417 | Myxoid smooth muscle neoplasia of the uterus: comprehensive analysis by next-generation sequencing and nucleic acid hybridization |
| Q89121807 | Nearing saturation of cancer driver gene discovery |
| Q89965697 | Neoantigens in Hematologic Malignancies |
| Q92539066 | Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy? |
| Q64989110 | Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). |
| Q90428632 | New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? |
| Q91238280 | Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer |
| Q38599122 | Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience |
| Q47926486 | Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance |
| Q97546037 | Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens |
| Q55209598 | Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors. |
| Q97070215 | Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas |
| Q90464942 | Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial |
| Q52586565 | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. |
| Q93377901 | Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation |
| Q61455084 | Novel insights into endothelial cell malignancies |
| Q98282392 | Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study |
| Q90065952 | Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial |
| Q47120629 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? |
| Q64066416 | PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers |
| Q64056211 | PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer |
| Q94570472 | PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer |
| Q92932037 | PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies |
| Q64053621 | Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma |
| Q99408618 | Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma |
| Q55497366 | Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). |
| Q95933711 | Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions |
| Q47566281 | Pancreatic cancer: Next-generation algorithms for neoantigen selection. |
| Q97545564 | Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report |
| Q64905379 | Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing. |
| Q48156858 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy |
| Q98186316 | Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors |
| Q64914214 | Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. |
| Q93052152 | Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses |
| Q92431353 | Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy |
| Q55029444 | Perspectives on the clinical development of immunotherapy in prostate cancer. |
| Q64086368 | Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer |
| Q91327123 | Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer |
| Q64114943 | Phenotype of POLE-mutated endometrial cancer |
| Q90024264 | Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness |
| Q57461763 | Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma |
| Q64107259 | Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives |
| Q55012383 | Precision Medicine in Head and Neck Cancer: Myth or Reality? |
| Q92982809 | Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We're Headed |
| Q92991548 | Preclinical murine tumor models: a structural and functional perspective |
| Q96155607 | Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers |
| Q57815797 | Predictive biomarkers for tumor immune checkpoint blockade |
| Q57299127 | Predictive pathology of lung cancer immunotherapy response |
| Q89497142 | Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC |
| Q89103577 | Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors |
| Q64958062 | Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. |
| Q90579990 | Primary CNS lymphoma commonly expresses immune response biomarkers |
| Q89983786 | Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis |
| Q99237681 | Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors |
| Q57159515 | Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes |
| Q64939796 | RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. |
| Q90441620 | RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines |
| Q57798069 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma |
| Q49797507 | Rational Design for Cervical Cancer Therapeutics: Cellular and Non-Cellular Based Strategies on the Horizon for Recurrent, Metastatic or Refractory Cervical Cancer. |
| Q96765678 | Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients |
| Q94525816 | Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review |
| Q100737233 | Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary |
| Q90157690 | Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review |
| Q90639891 | Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer |
| Q89537473 | Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle |
| Q42363061 | Resources for Interpreting Variants in Precision Genomic Oncology Applications |
| Q88993176 | Rethinking medulloblastoma from a targeted therapeutics perspective |
| Q90353808 | Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC |
| Q62648881 | Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers |
| Q64114357 | SALMON: Survival Analysis Learning With Multi-Omics Neural Networks on Breast Cancer |
| Q92691441 | SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association |
| Q52648065 | Salivary gland cancer patient-derived xenografts enable characterization of cancer stem cells and new gene fusions associated with tumor progression. |
| Q55379483 | Sarcoma-The standard-bearer in cancer discovery. |
| Q91891970 | Sex-associated molecular differences for cancer immunotherapy |
| Q64108704 | Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis |
| Q49715015 | Shed Skin Cancer, Not Collagen XVII: A New Approach to Targeting Skin Cancer Progression |
| Q90172521 | Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies |
| Q92721586 | Single-molecule detection of cancer mutations using a novel PCR-LDR-qPCR assay |
| Q92925160 | Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing |
| Q92083308 | Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer |
| Q104486593 | Somatic alterations and mutational burden are potential predictive factors for metachronous development of early gastric cancer |
| Q92593269 | Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients |
| Q91612580 | Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type |
| Q98289241 | Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors |
| Q57813172 | Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing |
| Q98613255 | Spontaneous mutations in the single TTN gene represent high tumor mutation burden |
| Q89659885 | Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies |
| Q55282202 | Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. |
| Q59127261 | Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report |
| Q100504573 | Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment |
| Q50001757 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. |
| Q58054909 | TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw |
| Q92337932 | Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma |
| Q92644009 | Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer |
| Q61797340 | Targeted mutation detection in breast cancer using MammaSeq™ |
| Q89622149 | Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer? |
| Q48234912 | Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. |
| Q97905239 | Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition |
| Q89510215 | Targeting the Immune system and Epigenetic Landscape of Urological Tumors |
| Q89668311 | Testing microsatellite instability in solid tumors: the ideal versus what is real |
| Q93165232 | The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer |
| Q92533583 | The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy |
| Q90452290 | The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy |
| Q55725588 | The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. |
| Q98386118 | The epigenomics of sarcoma |
| Q90402575 | The evolving immunotherapeutic landscape in advanced oesophagogastric cancer |
| Q91520697 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy |
| Q103728292 | The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies |
| Q98290541 | The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
| Q64930481 | The genomic mutation spectrums of breast fibroadenomas in Chinese population by whole exome sequencing analysis. |
| Q64079170 | The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies |
| Q102152400 | The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients |
| Q90281646 | The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy |
| Q93182663 | The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer |
| Q94599849 | The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities |
| Q55314072 | The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients. |
| Q64926466 | Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. |
| Q91861384 | Towards quantitative and multiplexed in vivo functional cancer genomics |
| Q94553390 | Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer |
| Q99633734 | Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer |
| Q47270933 | Tumor Mutational Burden and Response Rate to PD-1 Inhibition. |
| Q90440514 | Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence |
| Q38611235 | Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers |
| Q64063973 | Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates |
| Q92350797 | Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy |
| Q91835885 | Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study |
| Q97524993 | Tumor mutation burden associated with miRNA-gene interaction outcome mediates the survival of patients with liver hepatocellular carcinoma |
| Q90612091 | Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method |
| Q98466949 | Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types |
| Q92579646 | Tumor mutation burden: from comprehensive mutational screening to the clinic |
| Q92593587 | Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers |
| Q92748351 | Tumor mutational burden |
| Q89531597 | Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer |
| Q94475710 | Tumor mutational burden and immune signatures interplay in renal cell carcinoma |
| Q59798099 | Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? |
| Q59798130 | Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view |
| Q90273707 | Tumor mutational burden is associated with poor outcomes in diffuse glioma |
| Q104618320 | Tumor mutational burden on cytological samples: A pilot study |
| Q91895975 | Tumor mutational burden quantification from targeted gene panels: major advancements and challenges |
| Q91140222 | Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions |
| Q62745707 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types |
| Q64106473 | Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene |
| Q93157712 | Tumor neoantigens: from basic research to clinical applications |
| Q98564973 | Understanding genomics and the immune environment of penile cancer to improve therapy |
| Q64262617 | Update on systemic therapy for colorectal cancer: biologics take sides |
| Q64107768 | Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer |
| Q89985173 | Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations |
| Q98613071 | When, why and how tumour clonal diversity predicts survival |
| Q92728818 | [Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer] |
| Q58084642 | [Predictive value of PD-L1 diagnostics] |
| Q89850600 | dbPepNeo: a manually curated database for human tumor neoantigen peptides |
| Q90438932 | ecTMB: a robust method to estimate and classify tumor mutational burden |
Search more.